Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 153

Sort by

Sort Order Select

Journal Articles

Updated analysis of survival and treatment evolution in european multiple myeloma patients (2012–2023) across 7 countries from the honeur network

Blood (2025) 146 (Supplement 1): 2803.

https://doi.org/10.1182/blood-2025-2803

Published: 2025

Journal Articles

Sequential therapy with fitcy preparative regimen for patients above the age of 70 years with active AML – a single center retrospective analysis

Odelia Amit, Gil Fridberg, Yakir Moshe, Inna Ospovat, Yehonatan Sherf, Dina Tshernichovsy, Chen Karni, Irit Avivi, Ron Ram

Blood (2025) 146 (Supplement 1): 5973.

https://doi.org/10.1182/blood-2025-5973

Published: 2025

Journal Articles

Results of the promise study from ~30,000 individuals screened for monoclonal gammopathies

Blood (2025) 146 (Supplement 1): 403.

https://doi.org/10.1182/blood-2025-403

Published: 2025

Journal Articles

Multimodal epigenetic microarray classifies AML, MDS and controls using peripheral blood

Miriam Neaman, Jasline Deek, Rita Haldar, Yakir Moshe, Moshe Mittelman, Irit Avivi, Amit Manor, Mika Bell, Roy Vitkon, Mor Levi, Karolis Sablauskas, Efstathios Kastritis, Tomas Papajik, Eva Kriegova, Yuval Ebenstein

Blood (2025) 146 (Supplement 1): 3509.

https://doi.org/10.1182/blood-2025-3509

Published: 2025

Journal Articles

Talquetamab induces deep responses in heavily pre-treated patients with systemic light-chain amyloidosis

Mohamad Ganayem, Moshe Gatt, Yaël Cohen, Irit Avivi, Tamir Shragai

Blood (2025) 146 (Supplement 1): 7491.

https://doi.org/10.1182/blood-2025-7491

Published: 2025

Journal Articles

Distinct and non-overlapping epigenetic signatures differentiate MPN subtypes and reveal hydroxyurea-induced remodeling

Sigal Avraham, Miriam Neaman, Jasline Deek, Shir Michowitz, Irit Avivi, Ilana Sofronyuk, Yuval Ebenstein, Maya Koren-Michowitz

Blood (2025) 146 (Supplement 1): 3765.

https://doi.org/10.1182/blood-2025-3765

Published: 2025

Journal Articles

Mosunetuzumab (Mosun) or glofitamab (Glofit) in combination with golcadomide (Golca) demonstrates a manageable safety profile and encouraging efficacy in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL)

Blood (2025) 146 (Supplement 1): 66.

https://doi.org/10.1182/blood-2025-66

Published: 2025

Journal Articles

Icans mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol – a pilot study

Gil Fridberg, Odelia Amit, Yehonatan Sherf, Chava Perry, Yair Herishanu, Erel Joffe, Tamir Shragai, Roy Vitkon, Meir Preis, Shosan Perk, Nadav Sarid, Sharon Ben Barouch, Ronit Gold, Chen Glait Santar, Irit Avivi

Blood (2025) 146 (Supplement 1): 1943.

https://doi.org/10.1182/blood-2025-1943

Published: 2025

Journal Articles

Safety and efficacy of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma from Phase 1b of redirectt-1: Results with an extended median follow-up of 3 years

Blood (2025) 146 (Supplement 1): 701.

https://doi.org/10.1182/blood-2025-701

Published: 2025

Journal Articles

Summary analysis of the phase 1a/b study with HBI0101, an academic anti-BCMA chimeric antigen receptor T-cell (CART) for relapsed/refractory multiple myeloma

Eyal Lebel, Nathalie Asherie, Shlomit Kfir-Erenfeld, Batia Avni, Sigal Grisariu, Shlomo Elias, Eran Zimran, Vladimir Vainstein, Shlomzion Aumann, Miri Assayag, Marina Krizhevskaya, Ekaterina Dikhter, Marjorie Pick, Yaël Cohen, Irit Avivi, Cyrille Cohen, Moshe Gatt, Polina Stepensky

Blood (2025) 146 (Supplement 1): 2379.

https://doi.org/10.1182/blood-2025-2379

Published: 2025

Journal Articles

Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study

Max S. Topp, Matthew Matasar, John N. Allan, Stephen M. Ansell, Jeffrey A. Barnes, Jon E. Arnason, Jean-Marie Michot, Neta Goldschmidt, Susan M. O’Brien, Uri Abadi, Irit Avivi, Yuan Cheng, Dina M. Flink, Min Zhu, Jurriaan Brouwer-Visser, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, Jennifer L. Crombie

Blood (2025) 145 (14): 1498–1509.

https://doi.org/10.1182/blood.2024027044

Published: 2025

Includes: Supplemental data

Journal Articles

Standardization Protocol to Mitigate Progression of Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) in Elderly Patients Treated with CD28 Co-Stimulatory Anti-CD19 CAR-T Cells - a Pilot Study

Gil Fridberg, Odelia Amit, Mohamad Ganayem, Felix Bukstein, Chava Perry, Irit Avivi Mazza, Ronit Gold, Ron Ram

Blood (2024) 144 (Supplement 1): 2086.

https://doi.org/10.1182/blood-2024-204837

Published: 2024

Journal Articles

Immune Biomarkers of Mechanism of Action of Epcoritamab (Epcor) Plus Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) in Frontline DLBCL

Neha Dixit, Binhuan Wang, Kevin Zhao, Catherine Thieblemont, Irit Avivi Mazza, David Lavie, Abraham Avigdor, Carlos Grande Garcia, Andrew J. Steele, Mostafa Seliem, Pegah Jafarinasabian, Edith Szafer Glusman

Blood (2024) 144 (Supplement 1): 1734.

https://doi.org/10.1182/blood-2024-200395

Published: 2024

Journal Articles

The Addition of Brentuximab Vedotin to ESHAP Significantly Increases the Rate of Metabolic Complete Remissions Vs Chemotherapy Alone. in Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma. Final Results of a Phase IIb Prospective Randomized Clinical Trial (BRESELIBET)

Blood (2024) 144 (Supplement 1): 3049.

https://doi.org/10.1182/blood-2024-211527

Published: 2024

Journal Articles

Treatment Journey of Octogenarian Patients Outside Clinical Trials

Dor Shpitzer, Yael C. Cohen, Tamir Shragai, Guy Melamed, Anat Reiner-Benaim, Irit Avivi Mazza

Blood (2024) 144 (Supplement 1): 3777.

https://doi.org/10.1182/blood-2024-205689

Published: 2024

Journal Articles

Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1-3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial

Blood (2024) 144 (Supplement 1): 1032.

https://doi.org/10.1182/blood-2024-201533

Published: 2024

Journal Articles

Efficacy of HBI0101, an Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 1030.

https://doi.org/10.1182/blood-2024-198225

Published: 2024

Journal Articles

Fixed-Duration Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from Arm 1 of the Epcore NHL-5 Trial

Ronit Gurion, Irit Avivi Mazza, Catherine Thieblemont, Won Seog Kim, Andras Masszi, Alejandro Martín García-Sancho, Zsolt Nagy, Benoit Tessoulin, Ana Jimenez Ubieto, Po-Shen Ko, Daniel Alan Kerr, II, Edwin E. Jeng, Satya Siddani, Neha Joshi, Neha Dixit, Mariana Sacchi, Pegah Jafarinasabian, Abraham Avigdor

Blood (2024) 144 (Supplement 1): 3110.

https://doi.org/10.1182/blood-2024-199301

Published: 2024

Journal Articles

Efficacy and Safety of Odronextamab Monotherapy in Patients (Pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR T-Cell Therapy: Primary Analysis from the ELM-1 Study

Matthew Matasar, Max S. Topp, John N. Allan, Stephen M. Ansell, Jeffrey A. Barnes, Jon E. Arnason, Jean-Marie Michot, Neta Goldschmidt, Susan M. O'Brien, Uri Abadi, Irit Avivi Mazza, Jingxian Cai, Julia Zecchini, Min Zhu, Jurriaan Brouwer-Visser, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, Jennifer L. Crombie

Blood (2024) 144 (Supplement 1): 866.

https://doi.org/10.1182/blood-2024-199155

Published: 2024

Journal Articles

Efficacy and Safety of Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for the Treatment of Relapsed and Refractory AL Amyloidosis

Blood (2024) 144 (Supplement 1): 894.

https://doi.org/10.1182/blood-2024-198256

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Updated analysis of survival and treatment evolution in european multiple myeloma patients (2012–2023) across 7 countries from the honeur network

Sequential therapy with fitcy preparative regimen for patients above the age of 70 years with active AML – a single center retrospective analysis

Results of the promise study from ~30,000 individuals screened for monoclonal gammopathies

Multimodal epigenetic microarray classifies AML, MDS and controls using peripheral blood

Talquetamab induces deep responses in heavily pre-treated patients with systemic light-chain amyloidosis

Distinct and non-overlapping epigenetic signatures differentiate MPN subtypes and reveal hydroxyurea-induced remodeling

Mosunetuzumab (Mosun) or glofitamab (Glofit) in combination with golcadomide (Golca) demonstrates a manageable safety profile and encouraging efficacy in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL)

Icans mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol – a pilot study

Safety and efficacy of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma from Phase 1b of redirectt-1: Results with an extended median follow-up of 3 years

Summary analysis of the phase 1a/b study with HBI0101, an academic anti-BCMA chimeric antigen receptor T-cell (CART) for relapsed/refractory multiple myeloma

Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study

Standardization Protocol to Mitigate Progression of Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) in Elderly Patients Treated with CD28 Co-Stimulatory Anti-CD19 CAR-T Cells - a Pilot Study

Immune Biomarkers of Mechanism of Action of Epcoritamab (Epcor) Plus Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) in Frontline DLBCL

The Addition of Brentuximab Vedotin to ESHAP Significantly Increases the Rate of Metabolic Complete Remissions Vs Chemotherapy Alone. in Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma. Final Results of a Phase IIb Prospective Randomized Clinical Trial (BRESELIBET)

Treatment Journey of Octogenarian Patients Outside Clinical Trials

Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1-3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial

Efficacy of HBI0101, an Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for Relapsed/Refractory Multiple Myeloma

Fixed-Duration Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from Arm 1 of the Epcore NHL-5 Trial

Efficacy and Safety of Odronextamab Monotherapy in Patients (Pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR T-Cell Therapy: Primary Analysis from the ELM-1 Study

Efficacy and Safety of Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for the Treatment of Relapsed and Refractory AL Amyloidosis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only